The online version of this article (https://doi.org/10.1007/s13300-019-00722-y) contains supplementary material, which is available to authorized users.
To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.10042994.
Real-world evidence on the effectiveness and safety of insulin degludec (IDeg) in patients with diabetes is a priority. We have therefore evaluated the effectiveness and safety of IDeg, including impact on metabolic control, glycemic variability, weight gain and hypoglycemia, in patients with type 1 diabetes under routine clinical practice conditions.
This was an observational longitudinal multicenter study. A retrospective chart review of all patients with type 1 diabetes who were switched from basal insulin to IDeg was performed, and temporal trends in clinical outcomes were assessed.
Data obtained from 195 patients, with a median age of 42.8 [interquartile range (IQR) 24.6–56.4] years and a median diabetes duration of 16 (IQR 10.0–28) years, were analyzed. Median follow-up was 9.5 (IQR 7.7–11.3) months. Improvements were found in glycated hemoglobin (− 0.34%; p < 0.0001), fasting blood glucose (− 24.82 mg/dL; p < 0.0001), post-prandial glucose (− 17.23 mg/dL; p = 0.0009), glycemic variability as indicated by standard deviation of blood glucose (− 5.67 mg/dL; p < 0.0001) and high blood glucose index (− 3.77; p < 0.0001). Body weight and body mass index remained substantially stable during the follow-up (− 0.18 kg; p = 0.56 and − 0.12; p = 0.42, respectively). Risk of nocturnal hypoglycemia decreased by 52% [incidence rate ratio 0.48; 95% confidence interval (CI) 0.29–0.77] and risk of total hypoglycemic episodes by 41% (incidence ratio 0.59; 95% CI 0.45–0.83). Basal and short-acting insulin doses decreased by − 1.4 and − 3.1 IU, respectively.
Switching patients with type 1 diabetes to IDeg from other basal insulins was associated with relevant improvements in metabolic control and glycemic variability without weight gain; the risk of hypoglycemic episodes also significantly declined.
Novo Nordisk S.p.A. unconditional grant.
European Medicines Agency. Insulin degludec. Summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPARProduct_Information/human/002498/WC500138940.pdf. Accessed Nov 2019.
Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489–97. CrossRef
Mathieu C, Hollander P, Miranda-Palma B, et al. “Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154–62. CrossRef
Davies MJ, Gross JL, Ono Y, et al. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014;16:922–30. CrossRef
Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2002;14:859–64. CrossRef
Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type 1 and type 2 diabetes. Diabetologia. 2002;45:937. CrossRef
Wild D, von Maltzahn R, Brohan E, Christensen T, Clauson P, Gonder-Frederick L. A critical review of the literature on fear of hypoglycemia in diabetes: implications for diabetes management and patient education. Patient Educ Couns. 2007;68:10–5. CrossRef
de Lusignan S, Crawford L, Munro N. Creating and using real-world evidence to answer questions about clinical effectiveness. J Innov Health Inf. 2015;22:368–73. CrossRef
Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2017;10:326–35. CrossRef
Tentolouris N, Knudsen ST, Lapolla A, et al. Switching “Real-World” diabetes patients to degludec from other basal insulins provides different clinical benefits according to their baseline glycemic control. Adv Ther. 2019;36:1201–10. CrossRef
Lualdi C, Silverii A, Dicembrini I, et al. Adjustment of insuline doses when switching from glargine 100 U/ml or detemir to degludec: an observational study. J Endocrinol Invest. 2019;42:319–26. CrossRef
Ponzani P, Berra C, Di Lelio A, et al. Impact of insulin degludec in type 2 diabetes: real-world data on effectiveness and safety. Diabetes Ther. 2018;9:2209–18. CrossRef
Siegmund T, Tentolouris N, Knudsen ST, et al. A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes. Diabetes Obes Metab. 2018;20:689–97. CrossRef
Bohn B, Zimmermann A, Wagner C, et al. Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry. Diabetes Res Clin Pract. 2017;29:52–8. CrossRef
Simioni N. Inpatient hyperglycemia management: the opportunities of a new basal insulin. Ital J Med. 2016;10:103–10. CrossRef
- Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
Alessandra Di Lelio
Paola Del Sindaco
Chiara Di Loreto
Maria Chiara Rossi
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II